2018
DOI: 10.1186/s13195-018-0424-5
|View full text |Cite
|
Sign up to set email alerts
|

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

Abstract: BackgroundWe investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ) immunoglobulin (Ig)G4 monoclonal antibody, on biomarkers of amyloid pathology, neurodegeneration, and disease progression in patients with mild-to-moderate Alzheimer’s disease (AD).MethodsThis double-blind, placebo-controlled, randomized phase II study enrolled patients with mild-to-moderate AD and a Mini-Mental State Examination (MMSE) score of 18–26. In part 1 of the study, patients were 2:1 randomized to receive low-dose … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

8
145
1

Year Published

2019
2019
2022
2022

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 124 publications
(163 citation statements)
references
References 40 publications
8
145
1
Order By: Relevance
“…The study design has been described, 7,8 and the administration regimens and patients contributing to this study are summarized in Figure 1, with demographic information in Tables 1 and 2, and a biomarker overview in Table 3. The study design has been described, 7,8 and the administration regimens and patients contributing to this study are summarized in Figure 1, with demographic information in Tables 1 and 2, and a biomarker overview in Table 3.…”
Section: Methodsmentioning
confidence: 99%
See 4 more Smart Citations
“…The study design has been described, 7,8 and the administration regimens and patients contributing to this study are summarized in Figure 1, with demographic information in Tables 1 and 2, and a biomarker overview in Table 3. The study design has been described, 7,8 and the administration regimens and patients contributing to this study are summarized in Figure 1, with demographic information in Tables 1 and 2, and a biomarker overview in Table 3.…”
Section: Methodsmentioning
confidence: 99%
“…7,8 Both ABBY and BLAZE were sequentially enrolled, starting with the subcutaneous (SC) arm and then the intravenous (IV) arm in each trial. Patient ages (50-80 years), sex, and Mini-Mental State Examination (MMSE) scores were closely similar to those of the overall ABBY and BLAZE populations.…”
Section: Methodsmentioning
confidence: 99%
See 3 more Smart Citations